Eloxx Pharmaceuticals (ELOX) Stock Overview
A clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ELOX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Eloxx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.55 |
| 52 Week High | US$0.75 |
| 52 Week Low | US$0.000001 |
| Beta | -151142.55 |
| 1 Month Change | 399.09% |
| 3 Month Change | n/a |
| 1 Year Change | 548,900.00% |
| 3 Year Change | -92.78% |
| 5 Year Change | -99.03% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELOX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 26,042.9% | -0.1% | -0.3% |
| 1Y | 548,900.0% | 38.7% | 26.7% |
Return vs Industry: ELOX exceeded the US Pharmaceuticals industry which returned 36.1% over the past year.
Return vs Market: ELOX exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| ELOX volatility | |
|---|---|
| ELOX Average Weekly Movement | 37,259.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ELOX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ELOX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10 | Sumit Aggarwal | www.eloxxpharma.com |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations.
Eloxx Pharmaceuticals, Inc. Fundamentals Summary
| ELOX fundamental statistics | |
|---|---|
| Market cap | US$378.70k |
| Earnings (TTM) | -US$8.04m |
| Revenue (TTM) | n/a |
Is ELOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELOX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.04m |
| Earnings | -US$8.04m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -155.9% |
How did ELOX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 16:00 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eloxx Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |